Medicine · 2025
Acquired hemophilia A in an elderly female with bullous pemphigoid: Case report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhongmei, Xu Junzhu
Аннотация
RATIONALE: Acquired hemophilia A (AHA) is a rare but life-threatening bleeding disorder, necessitating enhanced recognition in patients with concomitant autoimmune diseases.
PATIENT CONCERNS: A 91-year-old female with bullous pemphigoid presented with spontaneous subcutaneous bleeding and prolonged activated partial thromboplastin time.
DIAGNOSES: Laboratory investigations revealed a decrease in factor VIII activity to 6.4%, confirming the diagnosis of bullous pemphigoid-associated AHA.
INTERVENTIONS: The patient was subjected to monotherapy with glucocorticoids and supportive hemostatic measures.
OUTCOMES: Coagulation parameters normalized within 1 month, and no severe complications occurred.
LESSONS: This case highlights the importance of considering AHA in elderly patients with autoimmune diseases who present with unexplained bleeding. An individualized treatment strategy may improve clinical outcomes.
PATIENT CONCERNS: A 91-year-old female with bullous pemphigoid presented with spontaneous subcutaneous bleeding and prolonged activated partial thromboplastin time.
DIAGNOSES: Laboratory investigations revealed a decrease in factor VIII activity to 6.4%, confirming the diagnosis of bullous pemphigoid-associated AHA.
INTERVENTIONS: The patient was subjected to monotherapy with glucocorticoids and supportive hemostatic measures.
OUTCOMES: Coagulation parameters normalized within 1 month, and no severe complications occurred.
LESSONS: This case highlights the importance of considering AHA in elderly patients with autoimmune diseases who present with unexplained bleeding. An individualized treatment strategy may improve clinical outcomes.